We are IntechOpen,
the world's leading publisher of
Open Access books
Built by scientists, for scientists

4,800
Open access books available

122,000
International authors and editors

135M
Downloads

Our authors are among the

154
Countries delivered to

TOP 1%
most cited scientists

12.2%
Contributors from top 500 universities

BOOK CITATION INDEX
CLARIVATE ANALYTICS
INDEXED

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Mitochondrial Dysfunction on the Toxic Effects of Anticancer Agents— From Lab Bench to Bedside

Mariana Ponte Cardoso Ribeiro,
Armanda Emanuela Castro e Santos and
José Barata Antunes Custódio

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/59488

1. Introduction

Cancer will become a major cause of morbidity and mortality in the next decades. It is estimated that the global cancer rate may increase by 75 %, with predicted 22.2 million new cases by 2030 compared with 12.7 million cases in 2008 [1]. The scientific community has made tremendous efforts to develop new therapies to deal effectively with this growing problem. As the recent advances in cancer therapy are improving the cancer patient survival, the toxic effects promoted by anticancer agents have a higher potential impact on long-term outcomes.

Anticancer agents are known to cause severe toxic effects that should be anticipated and carefully monitored. Therapeutic regimens targeting the cell cycle also affect the proliferation of normal cells, such as blood cells in the bone marrow, cells in the digestive tract and hair follicles, resulting in neutropenia, hair loss, and gut toxicity. The side effects observed are dependent on the type of therapy, but they are generally reversible and disappear after the end of the treatment. However, some anticancer agents may also affect, sometimes in a permanent manner, the function of vital organs, such as the heart, kidney, liver and the nervous system. Some of these effects may develop during or shortly after treatment, or may only become apparent a long period after completion of the treatment; if this delay is long enough, it may correspond to the time of progression free survival and affect the benefit-risk balance [2, 3].

Both the liver and kidneys are vulnerable to the toxic effects of cancer therapy and also to the direct impact of cancer itself. The liver has a great capacity to resist injury and to regenerate, but this capacity also makes it susceptible to anticancer drugs toxicity [2]. Indeed, the liver

injury induced by anticancer drugs is a significant cause of morbidity and mortality. However, most of these reactions are idiosyncratic and are not typically dose-dependent [2, 4]. Diagnosing liver damage due to anticancer agents is particularly challenging because competing etiologies, such as hepatotoxicity due to the intake of other medications, opportunistic infections, radiation therapy, and pre-existing liver disease, are frequent and greatly affect the host's susceptibility to liver injury [2, 4]. The major mechanisms underlying chemotherapy-related hepatotoxicity are based on the production of reactive metabolites, immunological injury, or mitochondrial dysfunction [4]. On the other hand, the spectrum of cancer-associated renal disease has changed in the last decades, mainly due to the introduction of new chemo-radiotherapy regimens. Nevertheless, renal failure remains an important complication of cancer treatment [5, 6]. Considering that drugs are primarily metabolized in the liver and excreted by the kidneys, hepatic and renal impairment can have an unpredictable impact on the metabolism and clearance of drugs that may ultimately affect the treatment outcome and toxicity.

In addition, cardiotoxicity is a common complication not only related to conventional cancer therapy, such as anthracyclines, but also to new antitumoral targeted therapy, such as trastuzumab. Due to the increasing number of patients treated with these agents, the incidence of cardiotoxicity is continuously growing and strongly affecting the patients' quality of life and overall survival, regardless of the oncologic prognosis [3]. Also, peripheral neuropathy is reported by 30-40 % of the patients and is one of the major reasons responsible for cessation of treatment [7]. Certain structural and functional features of peripheral nervous system make it more vulnerable to the action of anticancer drugs, namely the absence of a vascular barrier and of lymph drainage [7]. Furthermore, mammalian nerves are more susceptible to oxidative stress because of their high content of phospholipids, mitochondria rich axoplasm and weak cellular antioxidant defenses. Moreover, the enhanced free radical production promoted by anticancer drugs causes physical damage to neurons [7].

A thorough understanding of the mechanisms of injury is therefore a matter of great importance since it may contribute to detect toxic mechanisms at an early stage of drug development and, importantly, it can contribute to develop strategies aiming to minimize the toxicity. Mitochondrial dysfunction often underlies drug-induced toxicity and the works published over the last years point out that some of the severe adverse effects promoted by anticancer agents involve the targeting of mitochondria [8-11]. The heart, the kidneys, and the central nervous system, which have high energetic demands and are heavily dependent on oxidative phosphorylation, are more prone to the impact of mitochondrial damage. On the other hand, considering the exposure to high concentrations of drugs, the liver is another common organ showing mitochondrial dysfunction [12].

This chapter aims to provide an overview of the mechanisms of mitochondrial dysfunction induced by anticancer drugs and their involvement in several adverse effects, and particularly liver damage. Finally, possible combinations of therapeutic drugs to minimize the mitochondrial dysfunction promoted by these agents are discussed.

2. Methods

We searched literature published in English language included in PubMed for the period of 1970 to 2014. The main keywords searched were "mitochondrial dysfunction", "anticancer drugs and toxicity" and "tissue failure". The remaining papers were found in the reference list of the searched publications.

3. Anticancer drugs-induced tissue injury: The role of mitochondrial dysfunction

Mitochondria are dynamic and multifunctional cytoplasmic organelles, which possess a double membrane: an outer membrane (OMM) that is essentially permeable to ions and solutes up to 14 kDa, and an inner membrane (IMM), which is folded, forming the cristae, which is impermeable to ions and polar molecules. In the IMM are located several transporters, including the ATP/ADP and the aspartate/malate transporters, among others that regulate the movements of molecules across the IMM, and also the multisubunit complexes involved in the oxidative phosphorylation. Between the OMM and the IMM is located the intermembrane space (IMS), whereas the space enclosed by the IMM is the matrix (Fig.1). The IMS contains proteins such as the adenylate kinase and the creatine kinase (CK), as well as the cytochrome c and the apoptosis-inducing factor (AIF), which translocate to the cytoplasm during the apoptotic process, and other proteins involved in cellular metabolism. The proteins involved in the Krebs cycle, in the fatty acid oxidation, as well as in the synthesis of the heme and steroids, are located in the matrix [8, 9, 12, 13]. The mitochondrial matrix also contains the mitochondrial DNA (mtDNA). Thus, mitochondria are not only responsible for the synthesis of most of the ATP produced in the cell, but they also play a role in the fatty acid oxidation, the synthesis of the heme, steroids, and polypeptides involved in energy generation, as well as in calcium regulation and cell death. Therefore, taken in account the multitude of essential functions of mitochondria in cells, it is expected that their dysfunction might promote tissue failure, as described below.

3.1. Disturbance of mitochondrial energy production

The NADH and FADH$_2$ generated in metabolic pathways, including glycolysis, fatty acid oxidation and Krebs cycle are oxidized by complexes I and II of the mitochondrial electron transport chain, respectively. The electrons liberated are then passed to ubiquinone (coenzyme Q) that shuttles electrons to complex III, where it is oxidized; the electrons are then passed to complex IV through cytochrome c. The electrons carried by cytochrome c are used by complex IV to reduce molecular oxygen to water (Fig.1) [8, 14]. According to Peter Mitchell's Chemiosmotic Theory, complexes I, III and IV are redox-driven proton pumps that harness the energy derived from oxidation-reduction reactions to pump protons into the IMS, in parallel to the electron transfer, creating the electrochemical proton gradient (proton motive force) ($\Delta\mu H^+$), which is comprised of two components: a pH gradient (ΔpH)

and a membrane potential ($\Delta\Psi$) (Fig. 1). The complex V (ATP synthase), which consists of the F1 subunit, a soluble portion located in the mitochondrial matrix, and the Fo subunit, bound to the IMM, uses the electrical component $\Delta\Psi$ to phosphorylate ADP to ATP. Thus, the oxidative phosphorylation is coupled to the ATP requirements and the electron flow along the electron transport chain only occurs when the synthesis of ATP is required. The IMM impermeability ensures that the proton pumping along the respiratory chain is coupled to ATP synthesis [8, 12, 14].


Induction/inhibition of the mitochondrial permeability transition
All-*trans*-retinoic acid, paclitaxel, doxorubicin, etoposide, cisplatin, cyclophosphamide, tamoxifen

Changes in redox regulation
Flutamide, doxorubicin, paclitaxel, 6-mercaptopurine, busulfan, cisplatin, methotrexate, trastuzumab

Mitochondrial DNA damage
Tamoxifen, cisplatin, doxorubicin

Disturbance of mitochondrial energy production
Tamoxifen, flutamide, all-*trans*-retinoic acid, cisplatin, oxaliplatin, 6-mercaptopurine, ifosfamide, methotrexate, paclitaxel, doxorubicin, sorafenib, sunitinib, bortezomib

Figure 1. Structure of mitochondria and main mechanisms by which anticancer agents affect mitochondrial functions. Drugs can compromise mitochondrial bioenergetic functions by interfering with the generation system of $\Delta\mu H^+$, by dissipating the transmembrane proton gradient and by directly affecting the complex V or the substrate transporters. Drugs can also trigger or inhibit the mitochondrial permeability transition (MPT) by interfering with the proteins that compose or regulate the MPT or by modulating the critical factors to its onset, which may ultimately lead to cell death. Other drugs induce changes in the redox regulation of mitochondrial functions, promoting several deleterious events, including the interference with oxidative phosphorylation, nutrient oxidation and MPT. Drugs can also damage the mtDNA and, indirectly, compromise the ATP synthesis and favor the production of ROS (ANT, adenine nucleotide translocase; CyPD, cyclophilin-D; Cytc, cytochrome *c*; mnSOD, manganese superoxide dismutase; mtDNA, mitochondrial DNA; PiC, phosphate carrier; Prx, glutathione peroxidase; Q, coenzyme Q).

Xenobiotics can affect mitochondrial bioenergetic functions either by interfering with the generation system of $\Delta\mu H^+$ or by causing the dissipation of the transmembrane proton gradient, as well as by affecting directly the F1Fo ATPase and the substrate transporters, including the adenine nucleotide translocase (ANT) and the phosphate–hydrogen co-transporter (phosphate carrier) (Fig.1) [14].

In fact, the inhibition of the electron transport chain by drugs may not only lead to ATP depletion, but also hinders the reoxidation of NADH and $FADH_2$ into NAD^+ and FAD, respectively, which are required for the activity of several dehydrogenases of the Krebs cycle

and the mitochondrial β-oxidation [15, 16]. In addition, the inhibition of the electron transport chain favors the accumulation of electrons in the electron transport system complexes that can escape and directly react with oxygen to form the superoxide anion radical [17]. The excessive reactive oxygen species (ROS) production can promote several deleterious events (described in more detail in section 3.3), but it is noteworthy that, in this context, both lipid accumulation and lipid peroxidation are favored [15, 16].

On the other hand, drugs can compromise the impermeability of the IMM to protons and dissipate the proton gradient impairing the production of ATP. The IMM impermeability can be surpassed by drugs that either disrupt the mitochondrial membranes or act as ionophores, uncouplers of the oxidative phosphorylation and inducers of the mitochondrial permeability transition (MPT) [12-14]. Moreover, drugs that interfere with the basic components of the phosphorylative system can also impair the production of ATP. These different effects on mitochondria induce changes in cellular bioenergetics, one of the key hallmarks in tissues.

3.2. Mitochondria in Ca^{2+}homeostasis: MPT-dependent cell death

Besides serving as the cells' primary energy source, mitochondria are implicated in the maintenance of calcium homeostasis through calcium uptake and release pathways. The rise of mitochondrial matrix free calcium concentration in the presence of a variety of sensitizing factors can lead to the opening of the MPT pore that may serve either the purpose of providing a fast calcium release or can convey both apoptotic and necrotic death signals.

MPT can be defined as an increase in the IMM permeability to solutes with molecular masses up to 1 500 Da, due to the opening of a voltage and calcium-dependent, cyclosporine A (CyA)-sensitive channel [18].

The molecular identity of the MPT pore is still under debate [19] (Fig. 1). Cyclophilin-D is the binding site for CyA, the golden standard of MPT inhibitors, and among the several components that have been proposed to play a role on MPT, cyclophilin-D is probably the most consensual. The ANT and the voltage-dependent anion channel (VDAC) were also considered key components of the MPT pore complex for many years. Knockout mice devoid of cyclophilin-D are resistant to necrosis promoted by ROS and calcium overload and the mitochondria isolated from the liver, heart and brain of these animals are resistant to MPT *in vitro* [20, 21]. Although these results support a central role for cyclophilin-D, MPT can occur even in the absence of cyclophilin-D if the calcium concentration is high enough [22]. Likewise, MPT can occur in mitochondria lacking ANT, although a higher concentration of calcium is required [23] and, therefore, the ANT is now considered a regulatory component of the MPT pore, rather than a structural one. Similar studies have excluded the VDAC as an essential component of MPT pore megacomplex [24].

The phosphate carrier was also proposed to play a key role in MPT [25], but a later study demonstrated that the reduction of phosphate carrier protein expression does not affect the MPT [26]. A more recent work suggested that the MPT pore complex is composed of ATP synthase dimers and pointed out that cyclophilin-D binds the lateral stalk of the ATP synthase

at the same site as benzodiazepine 423, increasing the sensitivity to calcium [27]. However, the composition of MPT still remains a contentious issue.

Besides the calcium concentration in the matrix, the level of oxidative stress is possibly the most critical factor regulating MPT pore opening. Indeed, both the ANT and cyclophilin D were shown to be modulated by S-oxidation reactions [28-29]. However, other factors may contribute as well: the depletion of adenine nucleotides and high concentrations of phosphate increase the sensitivity of MPT to calcium, while a low pH and a high (negative) $\Delta\Psi$ inhibit MPT pore opening [30].

Drugs can trigger MPT either by interfering with the proteins that compose or regulate the MPT or by modulating the critical factors to its onset (Fig.1) [8]. As a consequence of MPT pore opening, the IMM loses its impermeability to protons, which allows the movement of solutes between the matrix and the cytosol, the dysregulation of cellular ionic homeostasis and the dissipation of $\Delta\mu H^+$. Moreover, since the protein concentration is higher in the matrix, a high osmotic pressure is generated and may lead to mitochondrial swelling, rupture of OMM, and loss of proapoptotic proteins that may trigger the apoptotic pathway in the cytoplasm [30, 31]. These events, together with the bioenergetic failure and the redox catastrophe, can culminate in cell death; if there are no sufficient levels of ATP, necrotic death may predominate over apoptosis [32]. Thus, depending on the cell type involved, different pathological conditions can occur as consequence of MPT induction.

3.3. Changes in redox regulation of mitochondrial functions

During the transfer of electrons along the electron transport chain to oxygen, and particularly at complexes I and III, some of these electrons escape and directly react with oxygen. The univalent reduction of oxygen generates the superoxide anion radical, which is then dismutated by the mitochondrial manganese superoxide dismutase into hydrogen peroxide, a key ROS signaling molecule due to its longer half-life and capacity to diffuse through membranes. The hydrogen peroxide is detoxified into water by the mitochondrial glutathione peroxidase and hence, in normal circumstances, most of the ROS generated by the electron transport chain are neutralized by the mitochondrial antioxidant defenses (Fig.1) [17]. The accumulation of hydrogen peroxide can promote the oxidation of thiolic groups, irreversibly deactivating the protein; likewise, the superoxide anion disassembles Fe–S clusters in several Krebs cycle enzymes and in respiratory complexes, and can combine with nitric oxide to form the highly toxic peroxynitrite. In addition, high levels of ROS can lead to the production of hydroxyl radical, which indiscriminately oxidizes biological macromolecules [33]. Other sources that can contribute to the total mitochondrial ROS include 2-oxoglutarate dehydrogenase, pyruvate dehydrogenase, dihydroorotate dehydrogenase, sn-glycerol-3-phosphate dehydrogenase, electron transfer flavoprotein:ubiquinol oxidoreductase, p66shc/Cytochrome C, Mia40p/ Erv1p, and complex II [33]. When maintained within a certain concentration range, ROS act as important signaling molecules, contributing to the redox balance, which regulates the functions that assist the normal cellular physiology [33]. However, the excessive formation of ROS can promote a series of deleterious events that deregulate key mitochondrial functions,

including oxidative phosphorylation, nutrient oxidation and MPT, which may ultimately lead to cell death, tissue failure and have also a key role in disease pathogenesis [33].

3.4. Mitochondrial DNA damage

The mtDNA, maternally inherited, encodes 13 polypeptides that are subunits of the complexes I, III, IV and V, which are synthesized in mitochondrial ribosomes. The majority of the other mitochondrial proteins, including the subunits of complex II, are encoded by nuclear DNA, and imported into mitochondria after synthesis on cytosolic ribosomes [8-10].

The mtDNA is particularly vulnerable to the action of drugs, as it lacks histones, similarly to the bacterial DNA. Furthermore, the DNA repair mechanisms are less efficient that those of nuclear DNA. Therefore, and considering the proximity to the sites where ROS are routinely generated, the frequency of mtDNA mutation is much higher than that of nuclear DNA [13]. Mutations of mtDNA can seriously damage the respiratory chain as most of the polypeptides that form the respiratory chain complexes are encoded by mtDNA. As discussed in section 3.1., the impairment of the respiratory chain decreases the ATP synthesis capacity and enhances the production of ROS, which in turn will promote oxidative damage on several biomolecules, including the mtDNA itself, creating a vicious cycle that further enhances the insult [34].

4. Anticancer drugs impair mitochondria functions: relevance to tissue failure

In the last decades a large number of anticancer drugs have been reported to induce tissue failure by promoting changes in essential functions of mitochondria. The extent and type of mechanisms underlying the anticancer drug-induced mitochondrial dysfunctions are tissue-dependent and responsible for most of the idiosyncratic adverse drug responses.

In this section, we discuss some examples of the prominent members of different groups of anticancer drugs with evidences for the involvement of mitochondrial dysfunction in tissue impairment induced by these compounds.

4.1. Selective estrogen receptor modulators

Tamoxifen has been the endocrine therapy of choice for women with estrogen-receptor positive breast carcinoma over the last decades. Fatty liver is observed in more than 30 % of patients taking tamoxifen, which may persist after the discontinuation of the treatment [35, 36]. Nonalcoholic steatohepatitis, hepatic fibrosis, cirrhosis and hepatic necrosis were also reported [37-39].

Tamoxifen depresses the phosphorylation efficiency and the levels of ATP in a concentration-dependent manner in isolated rat liver mitochondria; these effects were attributed to a decrease in the active ANT content and a partial inhibition of the phosphate carrier [40, 41]. On the other

hand, tamoxifen uncouples liver mitochondria respiration [40, 42] and, at higher concentrations, tamoxifen disrupts membrane integrity [43-44], enhancing the proton leak [40]. Tamoxifen also inhibits the electron transfer along the electron transport chain [40, 42] and the flavin mononucleotide site of complex I was identified as the target of tamoxifen [45]. The interaction of tamoxifen with complex III and IV was also shown [42]. The fact that tamoxifen interferes with membrane dynamics [46] may also decrease the diffusional mobility of membrane proteins and the electron transfer along the electron transport chain [40]. Furthermore, an *in vivo* study pointed out that tamoxifen depletes hepatic mtDNA, which further contributes to inhibit mitochondrial electron transport chain activity, and triggers steatose in mouse liver [47]. Therefore, the effects promoted by tamoxifen on mitochondrial bioenergetics may contribute to the liver damage observed in patients taking tamoxifen (Fig.1).

Interestingly, tamoxifen active metabolites, 4-hydroxytamoxifen and endoxifen, which are responsible for the antitumor actions of tamoxifen [48], do not significantly compromise mitochondrial bioenergetics at the concentrations reached in tissues [49, 50]. These results may indicate that the clinical use of tamoxifen metabolites instead of the prodrug may minimize liver damage. As the outcome of tamoxifen treatment seems to rely on its metabolic activation and endoxifen is a promising drug for cancer treatment, the future utilization of tamoxifen metabolites, and especially endoxifen, deserves further investigation. On the other hand, tamoxifen prevents and reverses the MPT induced by several agents [51-55]. Likewise, tamoxifen metabolites 4-hydroxytamoxifen and endoxifen also prevent and reverse the MPT induced by calcium and phosphate [50, 56]. Although the mechanisms underlying the inhibition of MPT by the antiestrogens are still under debate [57], this protective effect of TAM and its active metabolites regarding MPT might be of interest when considering combined anticancer drug therapies since it can decrease the toxicity of the associated drugs, as discussed in section 5.

4.2. Antiandrogens

Flutamide is a nonsteroidal anti-androgen used in the treatment of advanced prostate cancer, which has been associated with idiosyncratic drug-induced liver injury [58] and, although the mechanisms underlying liver damage are still unknown, mitochondria are a potential target of flutamide.

Indeed, high-doses of flutamide promote hepatocytes death in heterozygous Sod2(+/-) mice, but not in wild-type animals, suggesting that flutamide may exacerbate underlying mitochondrial abnormality [59]. Flutamide leads to the covalent binding of reactive electrophilic metabolites to proteins and diminishes the reduced glutathione (GSH)/glutathione disulfide (GSSG) ratio, as well as the total protein thiols in isolated rat hepatocytes; these effects are associated with the release of lactate dehydrogenase (LDH) [60]. Similar findings were reported by others, which also demonstrated that flutamide increases the hepatic GSSG/GSH ratio, the protein carbonyl levels, and serum lactate levels, supporting the view that the liver damage promoted by flutamide involves oxidative stress and mitochondrondrial dysfunction [59]. Accordingly, the addition of cysteine increased hepatocellular GSH and decreased LDH release in male hepatocytes [60].

Additionally, flutamide markedly impairs rat liver mitochondrial respiration (mainly at the level of complex I) and decreases the levels of ATP in rat hepatocytes [60]. Moreover, flutamide-treated Sod2(+/-) mice present a decrease in the expression of complexes I and III subunits [59]. Therefore, it seems possible that the increased oxidative stress promoted by flutamide may damage mitochondrial proteins and mtDNA, particularly when the antioxidant system is compromised [59], contributing to liver damage (Fig.1).

4.3. Alkylating agents

4.3.1. Platinum analogs

Cisplatin, which crosslinks DNA, is widely used in the treatment of head, neck, bladder ovarian and testicular cancers, but it has also been used in the management of other malignancies. Unfortunately, cisplatin promotes severe side effects, and particularly nephrotoxicity [61] and neurotoxicity [62].

Peripheral neuropathy is the dose limiting side effect of cisplatin and occurs in 30 % of patients. Dorsal root ganglion neurons treated with cisplatin exhibit mitochondrial vacuolization and degradation both *in vitro* and *in vivo*, suggesting that mitochondrial damage is involved in cisplatin-induced neurotoxicity (Fig.1) [63]. Besides covalently binding to nuclear DNA [64], cisplatin also directly binds to mtDNA, hindering the transcription of mitochondrial genes [63]. Another platinum analog, oxaliplatin, affects both complex I- and complex II-mediated respiration and decreases ATP production in rat peripheral nerve axons [65]. Acetyl-l-carnitine, which inhibits the development of oxaliplatin-evoked neuropathy, prevents oxaliplatin-induced mitochondrial dysfunction, further implicating mitochondria in the etiology of peripheral neuropathy [65].

About a quarter to one third of patients undergoing cisplatin treatment experience nephrotoxicity, which is manifested clinically as lower glomerular filtration rate and reduced serum magnesium and potassium levels [61]. Although the mechanism underlying cisplatin nephrotoxicity is not yet clear, the available evidence suggests that mitochondrial dysfunction plays a key role in renal tubular cell injury and death. Ultrastructural analysis of cisplatin-treated renal tubular cells of mouse kidney demonstrates the decrease in mitochondrial mass, disruption of cristae, and extensive mitochondrial swelling [66], supporting the involvement of mitochondria in cisplatin-induced nephrotoxicity. Cisplatin decreases manganese superoxide dismutase and complex II activity in rodents' kidney [67]. The GSH-reductase activity and the levels of GSH are markedly diminished in porcine proximal tubular cells [68]. These observations suggest that cisplatin strongly reduces the antioxidant defenses and favors ROS formation. However, agents that are able to prevent ROS formation, do not prevent cell death, suggesting that ROS formation is not the direct cause of cell death [68]. Furthermore, cisplatin significantly impairs kidney mitochondrial bioenergetic functions. In porcine proximal tubular cells, cisplatin inhibits complexes I to IV and decreases intracellular ATP [68]. In fact, the kidney of animals treated with cisplatin presents decreased mtDNA content and reduced complex I, III and IV protein expression [67].

Cisplatin is a rare cause of hepatotoxicity (steatosis and cholestasis) at standard doses, but high doses may lead to liver damage, revealed by abnormal liver tests, especially aspartate amino-transferase (AST) and alanine aminotransferase (ALT) [69]. Light microscopic observations confirmed that high doses of cisplatin cause massive hepatotoxicity; alterations at the ultra-structural level, including atrophied mitochondria, were also found [70]. Cisplatin induces MPT in rat liver mitochondria [71]. Moreover, cisplatin stimulates state 4 respiration, but does not affect FCCP-uncoupled respiration, suggesting that cisplatin affects mitochondrial bioenergetics by increasing the IMM permeability to protons and not by interfering with respiratory chain complexes activity [71]. Both the induction of MPT and the effects on liver mitochondrial bioenergetics are prevented by thiol group protecting agents, suggesting that changes on the redox-status of thiol groups affect membrane permeability to cations and underlie liver mitochondrial dysfunction [71]. Accordingly, it was proposed that the mechanism of cisplatin-induced hepatotoxicity involves membrane rigidification, lipid peroxidation, oxidative damage of cardiolipin and protein sulfhydryl groups, as well as decreased GSH/GSSG ratio, ATP, GSH and NADPH [72].

4.3.2. Nitrogen mustards

Cyclophosphamide is an alkylating agent used in the treatment of lymphomas, multiple myeloma, and certain types of leukemia, retinoblastoma, neuroblastoma, ovarian cancer, and breast cancer. Generally, cyclophosphamide does not cause relevant cardiotoxicity, but when it occurs, it appears to be related to a single dose, unlike the anthracyclines [3]. Patients who were previously medicated with anthracyclines or that underwent chest irradiation are more prone to suffer from cyclophosphamide-induced cardiotoxicity [3]. Liver damage was also reported [73, 74].

Cyclophosphamide compromises calcium accumulation by heart or liver mitochondria, which can almost be restored by CyA [75]. As the increases in the levels of serum AST, serum ALT, glucose-6-phosphate dehydrogenase and creatine phosphokinase induced by cyclophosphamide can also be attenuated by the simultaneous administration of CyA, the induction of MPT is closely related to the hepatotoxicity and cardiotoxicity promoted by cyclophosphamide (Fig.1) [75].

Ifosfamide, another nitrogen mustard, is one of the most commonly implicated drugs in kidney injury [76]. Using mitochondria isolated from the kidney of rats treated with ifosfamide, it was shown that this alkylating agent significantly inhibits complex I, resulting in NADH elevation and NAD^+depletion, and Krebs cycle impairment (Fig.1) [77]. Among the ifosfamide metabolites, only chloroacetaldehyde, which reaches high concentrations in the renal cortex, inhibits complex I, suggesting that this metabolite is responsible for the ifosfamide-induced nephrotoxicity [77].

4.3.3. Alkyl sulfonates

Busulfan is an alkylating drug, which forms DNA intrastrand crosslinks, used in the clinical management of chronic myelogenous leukemia. Although in standard doses busulfan rarely

causes liver dysfunction, some cases of hepatotoxicity during busulfan treatment were reported [78-80].

The toxicity of busulfan is thought to involve oxidative stress mechanisms as it promotes decreases in GSH in hepatocytes both *in vivo* and *in vitro* [81]. Considering that glutathione S-transferase inhibitors and antioxidants prevent busulfan toxicity *in vitro*, it is likely that busulfan toxicity requires glutathione conjugation [81] Moreover, the effects of busulfan are strongly exacerbated on GSH-depleted hepatoctyes [81], which may provide a basis to explain the enhanced sensitivity to the liver damaging effects of busulfan under certain circumstances.

4.4. Enzyme inhibitors

4.4.1. Anthracyclines

Doxorubicin is used in the clinical management of a wide range of cancers, and particularly in breast cancer treatment. The anticancer activity of doxorubicin involves its intercalation into DNA and disruption of topoisomerase-II-mediated DNA repair, as well as the generation of ROS that lead to lipid peroxidation, as well as membrane and DNA damage [82]. However, its therapeutic use is limited by its side-effects, mainly the dose-dependent myelosuppression and the cumulative and irreversible cardiotoxicity, which in the most severe forms may lead to patient death [83].

Acute cardiotoxicity occurs in less than 1 % of the patients immediately after infusion and is usually reversible; the early-onset chronic progressive form affects 1.6–2.1 % of patients, during therapy or within the first year after treatment; the late-onset chronic progressive form occurs after one year of completion of therapy in 1.6–5 % of patients, supporting the need of long-term follow-up [3]. Doxorubicin causes myocardial damage as shown by the increase in serum levels of AST, ALT, LDH isoenzyme and creatine phosphokinase isoenzyme [84]. Doxorubicin-induced cardiotoxicity etiology seems complex, and several effects may be involved, triggering a domino effect [83]. Among the several mechanisms postulated, the induction of oxidative stress is the most widely accepted. The univalent reduction of the tetracyclic ring of anthra-cycline by complex I generates a semiquinone free radical; the unpaired electron of this semiquinone is transferred to oxygen, forming the superoxide radical, while the tetracyclic ring returns to the parent quinone [85]. The free radicals generated are thought to be related to the interference with calcium homeostasis and bioenergetic functions, lipid peroxidation, and mtDNA damage, which play a key role in the pathogenesis of doxorubicin cardiotoxicity (Fig.1).

Heart mitochondria isolated from rats treated with doxorubicin present decreased state 3 respiration and respiratory control ratio (RCR), whereas the state 4 respiration is not affected [86-88]; complex I activity is also inhibited [87]. Besides affecting nuclear DNA, doxorubicin damages mtDNA [89-91] and decreases its content in human hearts [90]. Accordingly, doxorubicin-exposed human hearts show low activity of complex I and IV (encoded by mtDNA) but not of complex II (exclusively encoded by nuclear DNA) [90]. The higher levels of superoxide in doxorubicin-exposed hearts correlate negatively with mtDNA content and with the activities of respiratory chain complexes encoded by mtDNA [90]. The damage

leading to mtDNA adducts, as well as the higher rate of ROS formation and depression of GSH in heart tissue, persist for several weeks after cessation of doxorubicin treatment [92, 93].

Furthermore, mitochondria isolated from the heart of rats treated with doxorubicin present diminished ability to accumulate calcium [84, 86, 87, 94]. Similar effects were reported in mitochondria isolated from doxorubicin-treated human atrial trabeculae, and were shown to be reversed by CyA [95]. Considering that the decrease in left ventricular fractional survival promoted by doxorubicin is improved by the simultaneous administration of CyA, it seems that doxorubicin-induced heart damage is closely related to the induction of MPT pore opening [84, 96]. As discussed in section 3.3, oxidative stress is a major factor regulating MPT and doxorubicin leads to the oxidation of mitochondrial glutathione and to the accumulation of membrane disulfides, which may contribute to MPT induction. On the other hand, it has been proposed that the ANT is a key target for doxorubicin, as following doxorubicin treatment the amount of ANT protein and its active content are reduced in rats [94, 97]. The effects of doxorubicin on the ANT explain both the MPT induction and the effects on mitochondrial respiration [97]. Indeed, the decrease in state 3 respiration observed in heart mitochondria isolated from doxorubicin-treated rats is partially reversed by CyA or dithiothreitol, but not by trolox, suggesting that the toxic effects of doxorubicin on mitochondrial bioenergetics are at least in part a consequence of MPT induction and involve changes in the redox state of thiol groups [88]. Noteworthy, among several agents, including antioxidants, CyA was the only agent that was able to reverse the doxorubicin-induced alterations in the calcium accumulation capacity when added *ex vivo* [94]. Although the triggering of MPT by doxorubicin may initially involve the oxidation of regulatory components of the MPT pore megacomplex, once it occurs thiol protecting agents are unable to restore the pore to its original closed state [94, 98]. Therefore, antioxidants may be useful in the preventive setting, as discussed in section 5. Moreover, by increasing the generation of free radicals, doxorubicin also significantly enhances lipid peroxidation, as well as alterations in proteins and biomolecules that act as signaling molecules [99-101].

Altogether, the results obtained so far suggest that the persistent nature of doxorubicin cardiotoxicity reflects a self-perpetuating mechanism, where mtDNA alterations accumulate, leading to a damaged respiratory chain and decreased calcium loading ability; the defective respiratory chain further enhances ROS generation and mtDNA insult (Fig.1) [83, 98].

The heart is the main target of doxorubicin toxicity, due to the abundance of mitochondria in heart tissue, the elevated rate of oxygen consumption and the lower antioxidant defenses [83]. However, mitochondrial dysfunction has also been observed in other tissues. Indeed, in isolated mitochondrial fractions from the brain of rats treated with doxorubicin, the thiobarbituric acid-reactive substances and the vitamin E levels are increased, whereas the reduced glutathione content is diminished [102]. In addition, doxorubicin increases the sensibility of brain mitochondria to MTP pore opening [102]. The use of doxorubicin was also associated with a higher risk for developing hepatotoxicity among breast cancer patients [103]. Liver mitochondria isolated from doxorubicin-treated rats present decreased RCR and the activity of complex IV is inhibited [107]. In addition, light microscopic observations confirmed that

doxorubicin at high doses caused massive liver injury; alterations at the ultrastructural level, such as atrophied mitochondria, were shown [70].

4.4.2. Topoisomerase inhibitors

Etoposide is a podophyllotoxin derivative used in the treatment of several cancers that acts as a topoisomerase II inhibitor. Cases of hepatic injury were reported using either standard doses [104] or high-dose regimens [105]. Etoposide induces calcium-dependent MPT in rat liver mitochondria [106]. Since the etoposide-induced MPT is prevented by several antioxidants, it was proposed that etoposide triggers MPT pore opening through the generation of oxidant species, which is further corroborated by the ability of antioxidants to prevent the apoptosis promoted by etoposide (Fig.1) [107]. Therefore, the generation of oxidant species that are able to induce mitochondrial dysfunction may contribute to hepatic injury.

4.5. Antimicrotubules — Taxanes

Paclitaxel is a taxane-derived drug used in monotherapy or in combination with other agents, for the treatment of ovarian, breast and advanced non-small cell lung cancers, and AIDS-related Kaposi's sarcoma.

Painful peripheral neuropathy is the major dose-limiting side-effect of paclitaxel therapy, with the major drawback that the pain and sensory abnormalities can persist for months or years. Moreover, it may turn the patients unable to complete optimal chemotherapy schedules thus potentially compromising the treatment efficacy [108].

The involvement of mitochondrial dysfunction in paclitaxel-induced pain is suggested by the presence of swollen and vacuolated neuronal mitochondria [109]. Earlier investigations demonstrated that paclitaxel promotes a CyA-sensitive swelling in liver, kidney, heart, and brain mitochondria; the highest degree and slope of the swelling are observed in liver mitochondria, whereas the lowest are detected in brain mitochondria [110].

Using a rat model of paclitaxel-induced pain, it was shown that the non-specific ROS scavenger N-tert-butyl-α-phenylnitrone significantly decreases paclitaxel-induced mechanical hyper-sensitivity, whereas the superoxide selective scavenger 4-hydroxy-2, 2, 6, 6-tetramethylpiper-idine-1-oxyl (TEMPOL) does not present significant effects [108]. Therefore, the authors suggest that ROS are involved in the development and maintenance of paclitaxel-induced pain, although such effects cannot be attributed to superoxide radicals alone [108]. Moreover, rat sciatic nerve samples taken after induction of painful peripheral neuropathy with paclitaxel exhibit significant impairment of both complex I- and complex II-mediated respiration and deficits in ATP synthesis; the mitochondrial dysfunction promoted by paclitaxel is abrogated by acetyl-l-carnitine, again supporting that paclitaxel promotes oxidative damage [65].

Paclitaxel is extensively excreted by the liver, and therefore its administration to patients with liver impairment should be handled with care [69]. Alterations of liver functions are seen in 4-17 % of patients treated with doses up to 190 mg/m², but they can occur in 16-37 % of patients taking higher doses [69].

In isolated liver mitochondria, paclitaxel induces large amplitude swelling, the dissipation of mitochondrial membrane potential and the release of cytochrome c; these effects are inhibited by CyA, suggesting that paclitaxel induces MPT pore opening [110]. Paclitaxel also significantly increases complex IV-mediated ROS production (Fig.1) [110]. Paclitaxel does not inhibit mitochondrial respiration, but ROS formation is abolished by complex IV inhibitors, suggesting that paclitaxel promotes ROS production not by inhibiting the respiratory complexes, but through an effect on complex IV [110]. The abrogation of ROS formation does not prevent paclitaxel-induced MPT, suggesting that the induction of MPT is not secondary to enhanced ROS generation [110]. The combination with doxorubicin enhances the induction of oxidative stress [111].

The cardiotoxicity promoted by paclitaxel is usually represented by subclinical sinus brady-cardia (approximately 30 % of patients), but more severe conditions were also reported [3]. A recent study suggests that microtubule disorganization in cardiac myocytes promoted by paclitaxel leads to MTP pore opening [112]. However, when isolated mitochondria are exposed to paclitaxel, no significant effects are detected; the authors suggested that paclitaxel does not promote MPT due to a direct effect on mitochondria [112]. However, it must be noted that lower concentrations were used in the latter study in comparison with previous work using liver mitochondria [110, 112].

Therefore, both the induction of MPT and mitochondrial ROS production can contribute to paclitaxel side effects in the nerve, liver, kidney and heart.

4.6. Antimetabolites

4.6.1. Folate antagonists

Methotrexate is a folic acid antagonist widely used in the treatment of leukemia and other malignancies. Gastrointestinal toxicity and liver function abnormalities are common in patients taking methotrexate and the use of methotrexate in patients with history of liver disease is not advisable [113].

In liver mitochondria, methotrexate promotes a significant rise in superoxide radical formation, as well as in lipid peroxidation, whereas the GSH levels are decreased [114]. Likewise, methotrexate significantly impairs the function of isolated heart mitochondria by promoting lipid peroxidation, mitochondrial swelling and by inhibiting complex I, II and IV activities [115].

Methotrexate administration also leads to small intestinal injury and damages in enterocyte mitochondria, as shown by the decrease in the RCR, an indicator of mitochondrial function [116]. Moreover, the activities of complexes II and IV are markedly decreased in enterocyte mitochondria, suggesting that the deleterious effects promoted by methotrexate on enterocyte mitochondria can compromise ATP synthesis (Fig.1) [116], thereby leading to the gastrointestinal toxicity seen in patients.

4.6.2. Purine analogs

6-Mercaptopurine is an orally administered immunosuppressive drug used to treat acute lymphocytic leukemia. 6-Mercaptopurine is converted to its active metabolites, the 6-thioguanine nucleotides, or inactivated by xanthine oxidase or by thiopurine methyltransferase to 6-thiouric acid or 6-methylmercaptopurine, respectively [117]. Liver injury is an important adverse effect of 6-mercaptopurine, with an estimated frequency of liver test abnormalities within 1-9 % range [118]. Clinically relevant concentrations of 6-mercaptopurine are toxic to rat hepatocyte cultures by a mechanism that involves oxidative stress and ATP depletion (Fig. 1) [119]. The decreased rat hepatocytes viability promoted by 6-mercaptopurine is nearly prevented by allopurinol (xanthine oxidase inhibitor) together with trolox (vitamin E analog), implying xanthine oxidase-mediated metabolism of the thiopurines and oxidative stress in the hepatotoxicity promoted by 6-mercaptopurine [119].

4.7. Retinoids

All-*trans*-retinoic acid was approved in 1995 by the Food and Drug Administration for the treatment of acute promyelocytic leukemia, changing the outcome of this disease, which was associated with a significant mortality until then. Retinoids induce hepatotoxicity, either during dietary supplementation [120] or treatment of acute promyelocytic leukemia patients [121], and hypertriglyceridemia [122]. Moreover, vitamin A supplementation in rats induces slight enlargement of mitochondria [123], hepatic oxidative insult and mitochondrial dysfunction [124], supporting the view that mitochondria are a target of retinoid toxicity.

All-*trans*-retinoic acid is a known inducer of MPT pore opening [125-127], which is thought to reflect its ability to modulate ANT activity in both liver and heart mitochondria [126]. All-*trans*-retinoic acid depresses the phosphorylation efficiency of mitochondria and, at higher concentrations, induces uncoupling of mitochondria [127]. Whereas earlier studies attribute the uncoupling promoted by retinoids to an increase in the IMM permeability [128], a more recent study suggests that the leak of protons through the Fo fraction of complex V is the underlying mechanism [127]. Thus, is seems likely that the liver injury promoted by all-*trans*-retinoic acid reflects its effects on mitochondria (Fig.1).

4.8. Targeted therapy

4.8.1. Monoclonal antibodies

Trastuzumab is a recombinant humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), which is overexpressed by many adenocarcinomas. Trastuzumab improves cancer patient survival, but it also causes cardiotoxicity in a significant number of patients, ranging from 2-7 % when used as monotherapy, 2-13 % when used combined with paclitaxel, and up to 27 % when trastuzumab is used with both anthracyclines and cyclophosphamide [3]. In contrast to the cardiomyopathy promoted by doxorubicin, the cardiac dysfunction induced by trastuzumab does not appear to be dose dependent and is often reversible [123]. Neonatal rat cardiomyocytes treated with an inhibitory HER2 antibody

exhibit an increased ROS production and cell death, which are reversed by N-acetylcysteine and by CyA, suggesting that the toxic effects of trastuzumab on the heart involve mitochondrial damage and enhanced ROS production (Fig.1) [129].

4.8.2. Tyrosine kinase inhibitors

Sorafenib is effective against renal-cell carcinoma and hepatocellular carcinoma, whereas sunitinib is used in the management of advanced kidney cancer, gastrointestinal stromal tumor, and pancreatic neuroendocrine tumors. In phase I–II trials, 11 % of patients taking sunitinib experienced cardiovascular events and approximately half of the patients developed hypertension [130]. The incidence of sorafenib-associated heart toxicity is lower than that of sunitinib, and hypertension occurred in about 17 % of patients in clinical trials [131].

Sorafenib compromises mitochondrial function at clinically relevant concentrations in a myoblastic cell line grown under conditions where cells are either glycolytically or aerobically poised; the other tyrosine kinase inhibitors investigated (imatinib, dasatinib, sunitinib) do not affect the mitochondria [132]. Sorafenib uncouples heart mitochondria and inhibits complex V and complex II+III; at much higher concentrations the complex I and IV are also inhibited (Fig.1) [132].

Using neonatal rat cardiomyocyte cultures, it was shown that sunitinib decreases the mitochondrial membrane potential, and that both sunitinib and sorafenib reduce the intracellular ATP levels [133]. Echocardiographic abnormalities are apparent in sorafenib, but not in sunitinib or pazopanib treated animals; the analysis of ventricular cardiomyocytes revealed that sunitinib promotes mitochondrial swelling, dense deposits, and matrix cavitation, whereas sorafenib disrupted mitochondrial cristae [133].

4.8.3. Proteasome inhibitors

Bortezomib is a proteasome-inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma and its use in other types of cancer is currently under investigation. However, bortezomib induces dose-limiting peripheral neuropathy and compromises complex I- and complex II-mediated respiration, as well as ATP production in peripheral nerve axons, suggesting that mitochondrial dysfunction plays a key role in bortezomib-induced peripheral neuropathy (Fig.1) [134].

Mechanism	Drug class	Target organ	References
MPT			
MPT induction			
All-*trans*-retinoic acid	Miscellaneous agents	Heart and liver	[125-127]
Paclitaxel	Antimicrotubules	Heart, liver, kidney	[110]
Doxorubicin	Enzyme inhibitors	Heart and brain	[84, 86, 87, 94, 95, 102]
Etoposide	Enzyme inhibitors	Liver	[106]
Cisplatin	Alkylating agents	Liver	[71]

Mechanism	Drug class	Target organ	References
Cyclophosphamide	Alkylating agents	Heart and liver	[75]
MPT inhibition			
Tamoxifen	SERMs	Liver	[51-55]
Mitochondrial bioenergetics			
Tamoxifen	SERMs	Liver	[40, 41, 159]
Flutamide	Antiandrogens	Liver	[59, 60]
All-*trans*-retinoic acid	Miscellaneous agents	Liver	[127]
Cisplatin	Alkylating agents	Liver and kidney	[67, 68, 71]
Oxaliplatin	Alkylating agents	Nerve	[65]
6-Mercaptopurine	Antimetabolite	Liver	[119]
Ifosfamide	Alkylating agents	Kidney	[77]
Methotrexate	Antimetabolites	Heart and GI	[115, 116]
Paclitaxel	Antimicrotubules	Nerve	[65]
Doxorubicin	Enzyme inhibitors	Heart and liver	[86-88]
Sorafenib	Targeted Therapy	Heart	[132, 133]
Sunitinib	Targeted Therapy	Heart	[133]
Bortezomib	Targeted therapy	Nerve	[134]
mtDNA damage			
Tamoxifen	SERMs	Liver	[47]
Cisplatin	Alkylating agents	Neurons and kidney	[63, 67]
Doxorubicin	Enzyme inhibitors	Heart	[89-91]
Oxidative stress			
Flutamide	Antiandrogens	Liver	[59, 60]
Doxorubicin	Enzyme inhibitors	Heart and brain	[85, 102]
Paclitaxel	Antimicrotubules	Liver and nerve	[108, 110]
6-Mercaptopurine	Antimetabolites	Liver	[119]
Busulfan	Alkylating agents	Liver	[81]
Cisplatin	Alkylating agents	Kidney and liver	[67, 68, 72]
Methotrexate	Antimetabolites	Heart and liver	[114, 115]
Trastuzumab	Targeted therapy	Heart	[129]

Table 1. Summary of the mechanisms of mitochondrial dysfunction promoted by anticancer agents (GI, gastrointestinal tract; MPT, mitochondrial permeability transition; mtDNA, mitochondrial DNA; SERMs, selective estrogen receptors modulators).

5. A mitochondrial basis for anticancer drugs combinations: a promising approach to therapy

The severe toxicity promoted by anticancer agents represents a substantial health care burden that may seriously affect the treatment outcome. Based on the previous sections, mitochondria take center stage within the toxicity mechanisms, and are in the first line for protection by

pharmacological strategies aiming to avoid alterations that may prove deleterious both in the short and in the long term. Considering that some of these effects are irreversible or cumulative, it is desirable to prevent these events when planning the therapy of cancer patients.

As discussed in the previous section, oxidative stress has been established as one of the primary cause of mitochondrial dysfunction and toxicity induced by anticancer agents and, therefore, several antioxidants have been tested *in vitro* and *in vivo* as a prophylactic measure. In particular, naturally occurring antioxidants have been investigated as therapeutic adjuvants, as they are considered safe and well-tolerated, and may afford protection against cancer treatment-related toxicity by improving mitochondrial functions.

Alpha-lipoic acid affords protection against the neurotoxic effects promoted by cisplatin and paclitaxel through its antioxidant and mitochondrial regulatory functions [135]. The toxic effects promoted by cisplatin on rat liver mitochondria are also prevented by thiol group protecting agents [71]. Curcumin, which has anti-inflammatory and anticancerous properties, counteracts the mitochondrial lipid peroxidation and GSH levels alterations in mitochondria isolated from the brain and liver of rats treated with cisplatin, suggesting that it can abrogate the toxic effects of cisplatin on brain and liver [136]. Likewise, epicatechin prevents the renal damage and mitochondrial dysfunction promoted by cisplatin by decreasing oxidative stress; noteworthy, epicatechin does not compromise the antitumor actions of cisplatin in HeLa cells [67].

The etoposide-induced MPT is prevented by ascorbate, the primary reductant of the phenoxyl radicals generated by etoposide, and by thiol protecting agents [107].

An *in vitro* study demonstrated that Vitamin E decreases the oxidative stress induced by methotrexate in rat heart mitochondria and thereby minimizes mitochondrial dysfunction [115]. Likewise, the administration of lipoic acid decreases oxidative stress induced by methotrexate, which affects liver mitochondrial function [114].

Acetyl-L-carnitine completely blocks the effects of bortezomib on mitochondria and pain [134].

Strategies to prevent doxorubicin-induced cardiotoxicity are probably the best studied, given the significant number of patients affected and the impact on the overall success of the treatment. Many studies reported that antioxidants could afford cardioprotection against doxorubicin therapy. The broad antioxidant resveratrol markedly ameliorates the cardiac dysfunction promoted by doxorubicin, while the ROS generation is decreased, and gluta-thione, superoxide dismutase and catalase activities are improved [137]. Also, flavonoids, and particularly 7-monohydroxyethylrutoside, protect against the cardiac toxic effects promoted by doxorubicin both *in vitro* and *in vivo* [138]. In addition, 7-monohydroxyethylrutoside does not compromise the antitumor activity of doxorubicin in human ovarian cell lines and in the corresponding mouse xenograft models, and even inhibits the overexpression of adhesion molecules promoted by doxorubicin on vascular endothelial cells [138]. The combination of doxorubicin and vitamin E-succinate cooperates to induce apoptosis in human gastric cancer cells, by promoting doxorubicin influx and suppressing its efflux [139]. On the other hand, vitamin E also aggravates the heart damage promoted by doxorubicin in P388 tumor-bearing mice [140].

Studies in animals demonstrated that the inhibition of mitochondrial respiration and the decrease in mitochondrial calcium accumulation capacity promoted by doxorubicin are prevented by the coadministration of the beta-adrenergic receptor antagonist carvedilol [87]. The prophylactic use of carvedilol in patients receiving doxorubicin contributes to maintain left ventricle diameters constant and to preserve diastolic function [141]. Interestingly, the toxic effects promoted by doxorubicin on heart mitochondria and cardiac cell apoptosis are prevented by carvedilol, but not by atenolol, another beta-adrenergic receptor antagonist with no antioxidant action, suggesting that the antioxidant properties and not the beta-adrenergic receptor antagonism are responsible for the cardioprotective effects of carvedilol [142]. Likewise, metoprolol, which also has no antioxidative properties, failes to afford cardioprotection in lymphoma patients treated with doxorubicin [143].

Dexrazoxane, a well-studied therapeutic adjuvant for doxorubicin chemotherapy, is a free radical scavenger that was found to have cardioprotective effects by preventing the functional damage of cardiac mitochondria initiated by ROS [83, 144]. Dexrazoxane prevents or reduces cardiac injury in doxorubicin-treated children with acute lymphoblastic leukemia without affecting the antitumor activity of doxorubicin [145]. In contrast, other iron chelators have failed to afford the same degree of cardioprotection, suggesting that iron does not play a crucial role in the oxidative stress-mediated toxicity of doxorubicin [138, 146, 147].

Promising results were obtained when the potent phosphodiesterase-5 inhibitor sildenafil is combined with doxorubicin. Prophylactic treatment with sildenafil prevents cardiomyocyte apoptosis and left ventricular dysfunction in a mouse chronic model of doxorubicin-induced cardiotoxicity [148]. On the other hand, in breast cancer cells, sildenafil enhances sensitivity to doxorubicin without enhancing its toxicity in bone marrow cells or macrophages [149]. Furthermore, cotreatment with sildenafil enhances doxorubicin-induced apoptosis in prostate cancer cells and inhibits tumor growth in mice bearing prostate tumor xenografts, while attenuating left ventricular dysfunction promoted by doxorubicin [150].

Interesting results were also observed when retinoids and antiestrogens are combined. Antiestrogenic compounds inhibit the MPT-induced by retinoids in isolated liver mitochondria [127, 151, 152]. Noteworthy, the prevention of MPT by antiestrogens does not compromise the antitumor efficacy of all-*trans*-retinoic acid, as an additive/synergistic action was demonstrated in breast cancer [153-156] and melanoma [157] cell lines. Therefore, we propose that studies *in vivo* with combined therapies are now required to confirm that these results obtained *in vitro* will translate into more therapeutic benefits in humans while attenuate mitochondrial dysfunctions promoted by drugs used individually.

6. Concluding remarks

Considering the key role played by mitochondria in cell survival and death, the pharmacological modulation of mitochondrial activity has been investigated in cancer therapy [13, 158]. It is thought that this strategy may overcome the resistance mechanisms related with conventional chemotherapy that do not target mitochondria directly, but interfere with signaling

pathways which lie upstream of mitochondria and that are frequently deregulated in cancer [158]. However, the targeting of mitochondria as a therapeutic strategy is often compromised by the absence of significant pathophysiological differences between mitochondria in normal and malignant cells, leading to reduced selectivity of drugs targeting mitochondria. Therefore, the actions that are beneficial in cancer cells may, in contrast, underlie some of the severe toxic effects promoted by these agents.

Indeed, the induction of mitochondrial damage is an important contributor for some of the most well-known toxic effects of anticancer agents, namely the liver injury promoted by tamoxifen [159], the cardiotoxicity of doxorubicin or the cisplatin-induced neuropathy and nephrotoxicity. Organ dysfunction has a significant impact on the treatment outcomes and, therefore, the better understanding of the mechanisms of toxicity may unveil strategies to limit, or preferably to prevent, the incidence of these events and thereby improve the overall clinical success.

The recognition that mitochondrial dysfunction plays a key role in drug-induced toxicity may contribute to identify the drugs that are more likely to lead to such effects at an early stage. In this context, the use of isolated mitochondria fractions is a valuable tool to predict drug safety, since it provides relevant information while allowing to reduce the number of laboratory animals and the costs of preclinical studies [8].

On the other hand, our current knowledge does not allow to predict the idiosyncratic injury related with drug-induced mitochondrial dysfunction. It seems that genetic, metabolic and environmental factors that impair mitochondrial function can add their effects to those of anticancer drugs, compromising mitochondrial function to an extent where manifestations start to occur [17]. Therefore, therapeutic drug monitoring is mandatory. Furthermore, as organ damage may become apparent months or even years after the completion of the treatment (e.g. late-onset doxorubicin toxicity) the need of long-term follow-up is reinforced.

Finally, future studies should aim to develop strategies which are able to afford protection against both the short-term and long-term effects of anticancer drugs and without compromising their antitumor activity. Although antioxidants showed promise in *in vitro* studies, inconsistent results and failure in clinical trials turn the use of antioxidants as adjuvants in cancer therapy hardly consensual [7, 83]. However, in this context, we need to take into consideration that antioxidants may present different intracellular localization patterns and interfere with normal redox signaling pathways in specific cell compartments; an approach involving the targeted delivery of antioxidants to mitochondria can possibly provide better outcomes [7, 83]. Moreover, there are important differences between *in vitro* and *in vivo* toxicities and between animal models and humans. The different drug metabolism and clearance, as well as the asymmetries in redox regulation may account for the difficulty in translating these strategies into human subjects [83].

In conclusion, studies in suitable animal models are vital for a better understanding of the mechanisms underlying drug toxicity and the benefits of strategies aiming to prevent mitochondrial damage. So far most studies have used animal models devoid of tumors, which add an extra physiological burden that may influence the effects of drugs [83]. Moreover, as

described in the previous section, some of the toxic effects on mitochondria are observed in several organs, including the liver and kidneys, which may compromise both the pharmaco-kinetics and the efficacy of the anticancer drugs, but also the benefit of therapeutic adjuvants aiming to protect the mitochondria. These observations emphasize the importance of performing *in vivo* studies in relevant models, as well as the crucial importance of the clinical control and therapeutic drug monitoring of patients treated with anticancer drugs.

Author details

Mariana Ponte Cardoso Ribeiro, Armanda Emanuela Castro e Santos and
José Barata Antunes Custódio[*]

*Address all correspondence to: custodio@ci.uc.pt

Center for Neuroscience and Cell Biology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

References

[1] Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. The Lancet Oncology 2012;13(8): 790-801. http://www.ncbi.nlm.nih.gov/pubmed/22658655 (accessed 28 June 2014).

[2] Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicologic Pathology 2010;38(1): 142-7. http://www.ncbi.nlm.nih.gov/pubmed/19858501 (accessed 14 June 2014).

[3] Berardi R, Caramanti M, Savini A, Chiorrini S, Pierantoni C, Onofri A, Ballatore Z, De Lisa M, Mazzanti P, Cascinu S. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Critical Reviews in Oncology/Hematology 2013;88(1): 75-86. http://www.ncbi.nlm.nih.gov/pubmed/23522920 (accessed 8 July 2014).

[4] Bahirwani R, Reddy KR. Drug-Induced Liver Injury due to Cancer Chemotherapeutic Agents. Seminars in Liver Disease 2014;34(2): 162-71. http://www.ncbi.nlm.nih.gov/pubmed/24879981 (accessed 21 June 2014).

[5] Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. Journal of the American Society of Nephrology 2005;16(1): 151-61. http://www.ncbi.nlm.nih.gov/pubmed/15574506 (accessed 12 July 2014).

[6]   Skinner R, Kaplan R, Nathan PC. Renal and pulmonary late effects of cancer therapy. Seminars in Oncology 2013;40(6): 757-73. http://www.ncbi.nlm.nih.gov/pubmed/ 24331195 (accessed 27 July 2014).

[7]   Areti A, Yerra VG, Naidu V, Kumar A. Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy. Redox Biology 2014;2: 289-95. http:// www.ncbi.nlm.nih.gov/pubmed/24494204 (accessed 29 June 2014).

[8]   Pereira SP, Pereira GC, Moreno AJ, Oliveira PJ. Can drug safety be predicted and an- imal experiments reduced by using isolated mitochondrial fractions? Alternatives to Laboratory Animals: ATLA 2009;37(4): 355-65. http://www.ncbi.nlm.nih.gov/ pubmed/19807208 (accessed 12 June 2014).

[9]   Cohen BH. Pharmacologic effects on mitochondrial function. Developmental Disabil- ities Research Reviews 2010;16(2): 189-99. http://www.ncbi.nlm.nih.gov/pubmed/ 20818734 (accessed 13 July 2014).

[10] Nadanaciva S, Will Y. Investigating mitochondrial dysfunction to increase drug safe- ty in the pharmaceutical industry. Current Drug Targets 2011;12(6): 774-782. http:// www.ncbi.nlm.nih.gov/pubmed/21275886 (accessed 2 August 2014).

[11] Nadanaciva S, Will Y. New insights in drug-induced mitochondrial toxicity. Current Pharmaceutical Design 2011;17(20): 2100-2112. http://www.ncbi.nlm.nih.gov/ pubmed/21718246 (accessed 8 June 2014).

[12] Nadanaciva S, Will Y. Current concepts in drug-induced mitochondrial toxicity. In: Maines MD. (ed.) Current Protocols in Toxicology. Hoboken, NJ: John Wiley & Sons, Inc; 2009. p2.15.1-2.15.9. Available from http://www.ncbi.nlm.nih.gov/pubmed/ 20941696 (accessed 8 June 2014).

[13] Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B. The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. American Jour- nal of Physiology. Cell Physiology 2007;293(1): C12-C21. http:// www.ncbi.nlm.nih.gov/pubmed/17475665 (accessed 5 July 2014).

[14] Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annual Review of Pharmacology and Toxicology 2000;40: 353-88. http://www.ncbi.nlm.nih.gov/ pubmed/10836141 (accessed 29 July 2014).

[15] Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006;6(1): 1-28. http://www.ncbi.nlm.nih.gov/pubmed/16406828 (accessed 29 June 2014).

[16] Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology & Medicine 2012;52(1): 59-69. http://www.ncbi.nlm.nih.gov/pubmed/22064361 (accessed 14 July 2014).

[17] Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundamen-

tal & Clinical Pharmacology 2008;22(4): 335-53. http://www.ncbi.nlm.nih.gov/pubmed/18705745 (accessed 5 August 2014).

[18] Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 2007;12(5): 815-33. http://www.ncbi.nlm.nih.gov/pubmed/17294078 (accessed 19 July 2014).

[19] Siemen D, Ziemer M. What is the nature of the mitochondrial permeability transition pore and what is it not? IUBMB Life 2013;65(3): 255-62. http://www.ncbi.nlm.nih.gov/pubmed/23341030 (accessed 25 June 2014).

[20] Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005;434(7033): 658-62. http://www.ncbi.nlm.nih.gov/pubmed/15800627 (accessed 17 June 2014).

[21] Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005;434(7033): 652-8. http://www.ncbi.nlm.nih.gov/pubmed/15800626 (accessed 11 July 2014).

[22] Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. The Journal of Biological Chemistry 2005;280(19): 18558-61. http://www.ncbi.nlm.nih.gov/pubmed/15792954 (accessed 5 June 2014).

[23] Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004;427(6973): 461-5. http://www.ncbi.nlm.nih.gov/pubmed/14749836 (accessed 24 July 2014).

[24] Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nature Cell Biology 2007;9(5): 550-5. http://www.ncbi.nlm.nih.gov/pubmed/17417626 (accessed 17 July 2014).

[25] Leung AW, Varanyuwatana P, Halestrap AP. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. The Journal of Biological Chemistry 2008;283(39): 26312-23. http://www.ncbi.nlm.nih.gov/pubmed/18667415 (accessed 19 June 2014).

[26] Varanyuwatana P, Halestrap AP. The roles of phosphate and the phosphate carrier in the mitochondrial permeability transition pore. Mitochondrion 2012;12(1): 120-5. http://www.ncbi.nlm.nih.gov/pubmed/21586347 (accessed 1 July 2014).

[27] Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, Glick GD, Petronilli V, Zoratti M, Szabó I, Lippe G, Bernardi P. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proceedings of the National Academy of

Sciences of the United States of America 2013;110(15): 5887-92. http://www.ncbi.nlm.nih.gov/pubmed/23530243 (accessed 20 June 2014).

[28]   McStay GP, Clarke SJ, Halestrap AP. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochemical Journal 2002;367(Pt 2): 541-8. http://www.ncbi.nlm.nih.gov/pubmed/12149099 (accessed 30 June 2014).

[29]   Sánchez G, Fernández C, Montecinos L, Domenech RJ, Donoso P. Preconditioning tachycardia decreases the activity of the mitochondrial permeability transition pore in the dog heart. Biochemical and Biophysical Research Communications 2011;410(4): 916-21. http://www.ncbi.nlm.nih.gov/pubmed/21708132 (accessed 23 June 2014).

[30]   Halestrap AP. What is the mitochondrial permeability transition pore? Journal of Molecular and Cellular Cardiology 2009;46(6): 821-31. http://www.ncbi.nlm.nih.gov/pubmed/19017630 (accessed 21 June 2014).

[31]   Kinnally KW, Peixoto PM, Ryu SY, Dejean LM. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochimica et Biophysica Acta 2011;1813(4): 616-22. http://www.ncbi.nlm.nih.gov/pubmed/20888866 (accessed 22 July 2014).

[32]   Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Research in Cardiology 2009;104(2): 181-8. http://www.ncbi.nlm.nih.gov/pubmed/19242640 (accessed 25 June 2014).

[33]   Mailloux RJ, Jin X, Willmore WG. Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. Redox Biology 2014;2: 123-39. http://www.ncbi.nlm.nih.gov/pubmed/24455476 (accessed 11 June 2014).

[34]   Dalla Via L, García-Argáez AN, Martínez-Vázquez M, Grancara S, Martinis P, Toninello A. Mitochondrial permeability transition as target of anticancer drugs. Current Pharmaceutical Design 2014;20(2): 223-44. http://www.ncbi.nlm.nih.gov/pubmed/23701547 (accessed 12 July 2014).

[35]   Günel N, Coşkun U, Toruner FB, Sancak B, Yilmaz E, Cengiz O, Elbeg S, Uner A, Ozkan S. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis. Current Medical Research and Opinion 2003;19:47-50. http://www.ncbi.nlm.nih.gov/pubmed/12661780 (accessed 17 August 2014).

[36]   Liu CL, Huang JK, Cheng SP, Chang YC, Lee JJ, Liu TP. Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs 2006;17(6):709-13. http://www.ncbi.nlm.nih.gov/pubmed/16917217 (accessed 17 August 2014).

[37]   Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RN. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999;353(9146): 36-7. http://www.ncbi.nlm.nih.gov/pubmed/10023952 (accessed 25 July 2014).

[38]   Farrell GC. Drugs and steatohepatitis. Seminars in Liver Disease 2002;22(2): 185-94. http://www.ncbi.nlm.nih.gov/pubmed/12016549 (accessed 23 July 2014).

[39] Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009;115(14): 3189-95. http://www.ncbi.nlm.nih.gov/pubmed/19484789 (accessed 30 July 2014).

[40] Cardoso CMP, Custódio JBA, Almeida LM, Moreno AJM. Mechanisms of tamoxifen deleterious effects on the respiration rate and phosphorylation efficiency of mitochondria. Toxicology and Applied Pharmacology 2001;176(3): 145-52. http://www.ncbi.nlm.nih.gov/pubmed/11714246 (accessed 11 June 2014).

[41] Cardoso CM, Moreno AJ, Almeida LM, Custódio JB. Comparison of the changes in adenine nucleotides of rat liver mitochondria induced by tamoxifen and 4-hydroxy-tamoxifen. Toxicology In Vitro 2003;17(5-6): 663-70. http://www.ncbi.nlm.nih.gov/pubmed/15276871 (accessed 6 July 2014).

[42] Tuquet C, Dupont J, Mesneau A, Roussaux J. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biology and Toxicology 2000;16(4): 207-19. http://www.ncbi.nlm.nih.gov/pubmed/11101003 (accessed 9 July 2014).

[43] Custódio JB, Almeida LM, Madeira VM. The effect of the anticancer drugs tamoxifen and hydroxytamoxifen on the calcium pump of isolated sarcoplasmic reticulum vesicles. Toxicology In Vitro 1996;10(5): 523-31. http://www.ncbi.nlm.nih.gov/pubmed/20650233 (accessed 16 July 2014).

[44] Chen Y, Schindler M, Simon SM. A mechanism for tamoxifen-mediated inhibition of acidification. The Journal of Biological Chemistry 1999;274(26): 18364-73. http://www.ncbi.nlm.nih.gov/pubmed/10373441 (accessed 17 June 2014).

[45] Moreira PI, Custódio J, Moreno A, Oliveira CR, Santos MS. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. The Journal of Biological Chemistry 2006;281(15): 10143-52. http://www.ncbi.nlm.nih.gov/pubmed/16410252 (accessed 30 July 2014).

[46] Custódio JB, Almeida LM, Madeira VM. The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes. Biochimica et Biophysica Acta 1993;1150(2): 123-9. http://www.ncbi.nlm.nih.gov/pubmed/8347666 (accessed 8 June 2014).

[47] Larosche I, Lettéron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, Mansouri A. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. The Journal of Pharmacology and Experimental Therapeutics 2007;321(2): 526-35. http://www.ncbi.nlm.nih.gov/pubmed/17277197 (accessed 23 June 2014).

[48] Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemotherapy and Pharmacology 2005;55(5): 471-8. http://www.ncbi.nlm.nih.gov/pubmed/15685451 (accessed 17 August 2014).

[49] Cardoso CM, Moreno AJ, Almeida LM, Custódio JB. 4-Hydroxytamoxifen induces slight uncoupling of mitochondrial oxidative phosphorylation system in relation to the deleterious effects of tamoxifen. Toxicology 2002;179(3): 221-32. http://www.ncbi.nlm.nih.gov/pubmed/12270594 (accessed 27 June 2014).

[50] Ribeiro MP, Silva FS, Santos AE, Santos MS, Custódio JB. The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency. Toxicology and Applied Pharmacology 2013;267(1): 104-12. http://www.ncbi.nlm.nih.gov/pubmed/23274567 (accessed 8 June 2014).

[51] Custódio JBA, Moreno AJM, Wallace KB. Tamoxifen inhibits induction of the mitochondrial permeability transition by Ca^{2+}and inorganic phosphate. Toxicology and Applied Pharmacology 1998;152(1): 10-7. http://www.ncbi.nlm.nih.gov/pubmed/9772195 (accessed 9 July 2014).

[52] Cardoso CM, Almeida LM, Custódio JB. Protection of tamoxifen against oxidation of mitochondrial thiols and NAD(P)H underlying the permeability transition induced by prooxidants. Chemico-Biological Interactions 2004;148(3): 149-61. http://www.ncbi.nlm.nih.gov/pubmed/15276871 (accessed 5 June 2014).

[53] Moreira PI, Custódio JB, Nunes E, Moreno A, Seiça R, Oliveira CR, Santos MS. Estradiol affects liver mitochondrial function in ovariectomized and tamoxifen-treated ovariectomized female rats. Toxicology and Applied Pharmacology 2007;221(1): 102-10. http://www.ncbi.nlm.nih.gov/pubmed/17397887 (accessed 15 June 2014).

[54] Hernández-Esquivel L, Natalia-Pavón, Zazueta C, García N, Correa F, Chávez E. Protective action of tamoxifen on carboxyatractyloside-induced mitochondrial permeability transition. Life Sciences 2011;88(15-16): 681-7. http://www.ncbi.nlm.nih.gov/pubmed/21324322 (accessed 23 June 2014).

[55] Hernández-Esquivel L, Zazueta C, Buelna-Chontal M, Hernández-Reséndiz S, Pavón N, Chávez E. Protective behavior of tamoxifen against Hg2+-induced toxicity on kidney mitochondria: in vitro and in vivo experiments. The Journal of Steroid Biochemistry and Molecular Biology 2011;127(3-5): 345-50. http://www.ncbi.nlm.nih.gov/pubmed/21821123 (accessed 6 July 2014).

[56] Cardoso CM, Almeida LM, Custódio JB. 4-Hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition. Mitochondrion 2002;1(6): 485-95. http://www.ncbi.nlm.nih.gov/pubmed/16120301 (accessed 22 June 2014).

[57] Ribeiro MP, Santos AE, Custódio JB. Mitochondria: the gateway for tamoxifen-induced liver injury. Toxicology 2014;323C: 10-8. http://www.ncbi.nlm.nih.gov/pubmed/24881593 (accessed 4 August 2014).

[58] Bruni V, Peruzzi E, Dei M, Nannini S, Seravalli V, Sisti G, Fambrini M. Hepatotoxicity with low-and ultralow-dose flutamide: a surveillance study on 203 hyperandro-

genic young females. Fertility and Sterility 2012;98(4): 1047-52. http://www.ncbi.nlm.nih.gov/pubmed/22795685 (accessed 1 July 2014).

[59] Kashimshetty R, Desai VG, Kale VM, Lee T, Moland CL, Branham WS, New LS, Chan EC, Younis H, Boelsterli UA. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicology and Applied Pharmacology 2009;238(2): 150-9. http://www.ncbi.nlm.nih.gov/pubmed/19442681 (accessed 14 June 2014).

[60] Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, Pessayre D. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. Journal of Pharmacology and Experimental Therapeutics 1994;269(3): 954-62. http://www.ncbi.nlm.nih.gov/pubmed/8014883 (accessed 12 June 2014).

[61] Yang Y, Liu H, Liu F, Dong Z. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. Archives of Toxicology 2014;88(6): 1249-56. http://www.ncbi.nlm.nih.gov/pubmed/24859930 (accessed 23 July 2014).

[62] McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Molecular Cancer Therapeutics 2009;8(1): 10-6. http://www.ncbi.nlm.nih.gov/pubmed/19139108 (accessed 24 June 2014).

[63] Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, Schlattau A, Lathroum L, Windebank AJ. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiology of Disease 2011;41(3): 661-8. http://www.ncbi.nlm.nih.gov/pubmed/21145397 (accessed 14 August 2014).

[64] Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006;27(6): 992-1002. http://www.ncbi.nlm.nih.gov/pubmed/16797073 (accessed 12 June 2014).

[65] Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel-and oxaliplatin-evoked painful peripheral neuropathy. Experimental Neurology 2011;232(2): 154-61. http://www.ncbi.nlm.nih.gov/pubmed/21907196 (accessed 3 July 2014).

[66] Zsengellér ZK, Ellezian L, Brown D, Horváth B, Mukhopadhyay P, Kalyanaraman B, Parikh SM, Karumanchi SA, Stillman IE, Pacher P. Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity. The Journal of Histochemistry & Cytochemistry 2012;60(7): 521-9. http://www.ncbi.nlm.nih.gov/pubmed/22511597 (accessed 19 June 2014).

[67] Tanabe K, Tamura Y, Lanaspa MA, Miyazaki M, Suzuki N, Sato W, Maeshima Y, Schreiner GF, Villarreal FJ, Johnson RJ, Nakagawa T. Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. American Journal of Physiology. Renal Physiology 2012;303(9): F1264-74. http://www.ncbi.nlm.nih.gov/pubmed/22933302 (accessed 13 July 2014).

[68] Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. The Journal of Pharmacology and Experimental Therapeutics 1997;280(2): 638-49. http://www.ncbi.nlm.nih.gov/pubmed/9023274 (accessed 2 July 2014).

[69] King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001;6(2): 162-76. http://www.ncbi.nlm.nih.gov/pubmed/11306728 (accessed 17 July 2014).

[70] El-Sayyad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur RL, Fernando A, Raj MH, Ouhtit A. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. International Journal of Biological Sciences 2009;5(5): 466-73. http://www.ncbi.nlm.nih.gov/pubmed/19584954 (accessed 6 July 2014).

[71] Custódio JB, Cardoso CM, Santos MS, Almeida LM, Vicente JA, Fernandes MA. Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology 2009;259(1-2): 18-24. http://www.ncbi.nlm.nih.gov/pubmed/19428939 (accessed 27 June 2014).

[72] Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. Journal of Applied Toxicology 2008;28(3): 337-44. http://www.ncbi.nlm.nih.gov/pubmed/17604343 (accessed 3 August 2014).

[73] Mok CC, Wong WM, Shek TW, Ho CT, Lau CS, Lai CL. Cumulative hepatotoxicity induced by continuous low-dose cyclophosphamide therapy. The American Journal of Gastroenterology 2000;95(3): 845-6. http://www.ncbi.nlm.nih.gov/pubmed/10710110 (accessed 19 June 2014).

[74] Subramaniam SR, Cader RA, Mohd R, Yen KW, Ghafor HA. Low-dose cyclophosphamide-induced acute hepatotoxicity. The American Journal of Case Reports 2013;14: 345-9. http://www.ncbi.nlm.nih.gov/pubmed/24023976 (accessed 16 July 2014).

[75] Al-Nasser IA. In vivo prevention of cyclophosphamide-induced Ca2+dependent damage of rat heart and liver mitochondria by cyclosporin A. Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology. 1998;121(3): 209-14. http://www.ncbi.nlm.nih.gov/pubmed/9972318 (accessed 18 June 2014).

[76] Airy M, Raghavan R, Truong LD, Eknoyan G. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrology Dialysis Transplantation 2013;28(10): 2502-9. http://www.ncbi.nlm.nih.gov/pubmed/24009289 (accessed 14 June 2014).

[77] Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips PC, Yudkoff M. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Research

2006;66(15): 7824-31. http://www.ncbi.nlm.nih.gov/pubmed/16885387 (accessed 30 June 2014).

[78] Underwood JC, Shahani RT, Blackburn EK. Cholestatic jaundice following treatment of chronic granulocytic leukemia with busulphan. Journal of Clinical Pathology 1970;23(9): 827. http://www.ncbi.nlm.nih.gov/pubmed/5278972 (accessed 16 June 2014).

[79] Morris LE, Guthrie TH Jr. Busulfan-induced hepatitis. The American Journal of Gastroenterology 1988;83(6): 682-683. http://www.ncbi.nlm.nih.gov/pubmed/3376924 (accessed 19 June 2014).

[80] Adang RP, Breed WP. Liver damage during use of busulfan. Nederlands Tijdschrift voor Geneeskunde 1989;133(30): 1515-8. http://www.ncbi.nlm.nih.gov/pubmed/2797253 (accessed 23 June 2014).

[81] DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000;60(3): 143-54. http://www.ncbi.nlm.nih.gov/pubmed/10754451 (accessed 1 July 2014).

[82] Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and Genomics 2011;21(7): 440-6. http://www.ncbi.nlm.nih.gov/pubmed/21048526 (accessed 23 June 2014).

[83] Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Medical Research Reviews 2014;34(1): 106-35. http://www.ncbi.nlm.nih.gov/pubmed/23494977 (accessed 14 July 2014).

[84] Al-Nasser IA. In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506. Toxicology 1998;131(2-3): 175-81. http://www.ncbi.nlm.nih.gov/pubmed/9928632 (accessed 1 July 2014).

[85] Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Research 1983;43(2): 460-72. http://www.ncbi.nlm.nih.gov/pubmed/6293697 (accessed 2 July 2014).

[86] Solem LE, Henry TR, Wallace KB. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicology and Applied Pharmacology 1994;129(2): 214-22. http://www.ncbi.nlm.nih.gov/pubmed/7527602 (accessed 19 June 2014).

[87] Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicology and Applied Pharmacology 2002;185(3): 218-27. http://www.ncbi.nlm.nih.gov/pubmed/12498738 (accessed 11 August 2014).

[88] Oliveira PJ, Santos MS, Wallace KB. Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration. Biochemistry (Mos-

cow) 2006;71(2):194-99. http://www.ncbi.nlm.nih.gov/pubmed/16489925 (accessed 27 June 2014).

[89] Ellis CN, Ellis MB, Blakemore WS. Effect of adriamycin on heart mitochondrial DNA. The Biochemical Journal 1987;245(1): 309-12. http://www.ncbi.nlm.nih.gov/pubmed/3663157 (accessed 2 August 2014).

[90] Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. Journal of Pathology 2005;207(4): 436-44. http://www.ncbi.nlm.nih.gov/pubmed/16278810 (accessed 8 July 2014).

[91] Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochemical and Biophysical Research Communications 2009;378(3): 450-5. http://www.ncbi.nlm.nih.gov/pubmed/19032935 (accessed 7 July 2014).

[92] Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicology Letters 2001;121(3): 151-7. http://www.ncbi.nlm.nih.gov/pubmed/11369469 (accessed 27 July 2014).

[93] Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003;108(19): 2423-9. http://www.ncbi.nlm.nih.gov/pubmed/14568902 (accessed 17 June 2014).

[94] Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Research 2001;61(2): 771-7. http://www.ncbi.nlm.nih.gov/pubmed/11212281 (accessed 15 June 2014).

[95] Montaigne D, Marechal X, Preau S, Baccouch R, Modine T, Fayad G, Lancel S, Neviere R. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 2011;11(1): 22-6. http://www.ncbi.nlm.nih.gov/pubmed/20599629 (accessed 13 July 2014).

[96] Marechal X, Montaigne D, Marciniak C, Marchetti P, Hassoun SM, Beauvillain JC, Lancel S, Neviere R. Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Clinical Science 2011;121(9): 405-13. http://www.ncbi.nlm.nih.gov/pubmed/21605084 (accessed 2 July 2014).

[97] Oliveira PJ, Wallace KB. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats – relevance for mitochondrial dysfunction. Toxicology 2006;220(2-3): 160-8. http://www.ncbi.nlm.nih.gov/pubmed/16427179 (accessed 5 August 2014).

[98] Wallace KB. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovascular Toxicology 2007;7(2): 101-7. http://www.ncbi.nlm.nih.gov/pubmed/17652813 (accessed 18 June 2014).

[99] Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepato-cytes and enhancement of lipid peroxidation by adriamycin and 1, 3-bis(2-chloroeth-yl)-1-nitrosourea (BCNU). Biochemical Pharmacology 1983;32(8): 1383-8. http://www.ncbi.nlm.nih.gov/pubmed/6860357 (accessed 12 August 2014).

[100] Mimnaugh EG, Trush MA, Bhatnagar M, Gram TE. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adria-mycin. Biochemical Pharmacology 1985;34(6): 847-56. http://www.ncbi.nlm.nih.gov/pubmed/3977958 (accessed 7 July 2014).

[101] Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotox-icity. Cell Biology and Toxicology 2007;23(1): 15-25. http://www.ncbi.nlm.nih.gov/pubmed/17009097 (accessed 3 June 2014).

[102] Cardoso S, Santos RX, Carvalho C, Correia S, Pereira GC, Pereira SS, Oliveira PJ, San-tos MS, Proença T, Moreira PI. Doxorubicin increases the susceptibility of brain mito-chondria to Ca(2+)-induced permeability transition and oxidative damage. Free Radical Biology & Medicine 2008;45(10):1395-402. http://www.ncbi.nlm.nih.gov/pubmed/18775776 (accessed 21 June 2014).

[103] Damodar G, Smitha T, Gopinath S, Vijayakumar S, Rao Y. An evaluation of hepato-toxicity in breast cancer patients receiving injection Doxorubicin. Annals of Medical and Health Sciences Research 2014;4(1): 74-9. http://www.ncbi.nlm.nih.gov/pubmed/24669335 (accessed 19 June 2014).

[104] Tran A, Housset C, Boboc B, Tourani JM, Carnot F, Berthelot P. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. Journal of Hepatology 1991;12(1): 36-9. http://www.ncbi.nlm.nih.gov/pubmed/2007774 (accessed 22 July 2014).

[105] Johnson DH, Greco FA, Wolff SN. Etoposide-induced hepatic injury: a potential com-plication of high-dose therapy. Cancer Treatment Reports 1983;67(11): 1023-4. http://www.ncbi.nlm.nih.gov/pubmed/6315228 (accessed 10 August 2014).

[106] Custódio JB, Cardoso CM, Madeira VM, Almeida LM. Mitochondrial permeability transition induced by the anticancer drug etoposide. Toxicology In Vitro 2001;15(4-5): 265-70. http://www.ncbi.nlm.nih.gov/pubmed/11566547 (accessed 23 July 2014).

[107] Custódio JB, Cardoso CM, Almeida LM. Thiol protecting agents and antioxidants in-hibit the mitochondrial permeability transition promoted by etoposide: implications in the prevention of etoposide-induced apoptosis. Chemico-Biological Interactions 2002;140(2): 169-84. http://www.ncbi.nlm.nih.gov/pubmed/12076523 (accessed 14 June 2014).

[108] Fidanboylu M, Griffiths LA, Flatters SJ. Global inhibition of reactive oxygen species (ROS) inhibits paclitaxel-induced painful peripheral neuropathy. PLoS One 2011;6(9): e25212. http://www.ncbi.nlm.nih.gov/pubmed/21966458 (accessed 14 July 2014).

[109] Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006;122(3): 245-57. http://www.ncbi.nlm.nih.gov/pubmed/12016549 (accessed 1 August 2014).

[110] Varbiro G, Veres B, Gallyas F Jr, Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radical Biology & Medicine 2001;31(4):548-58. http://www.ncbi.nlm.nih.gov/pubmed/11498288 (accessed 3 August 2014).

[111] Pieniążek A, Czepas J, Piasecka-Zelga J, Gwoździński K, Koceva-Chyła A. Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Advances in Medical Sciences 2013;58(1): 104-11. http://www.ncbi.nlm.nih.gov/pubmed/23612702 (accessed 17 August 2014).

[112] Kumazawa A, Katoh H, Nonaka D, Watanabe T, Saotome M, Urushida T, Satoh H, Hayashi H. Microtubule disorganization affects the mitochondrial permeability transition pore in cardiac myocytes. Circulation Journal 2014;78(5): 1206-15. http://www.ncbi.nlm.nih.gov/pubmed/24614510 (accessed 13 July 2014).

[113] Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacological Reviews 2005;57(2): 163-72. http://www.ncbi.nlm.nih.gov/pubmed/15914465 (accessed 4 July 2014).

[114] Tabassum H, Parvez S, Pasha ST, Banerjee BD, Raisuddin S. Protective effect of lipoic acid against methotrexate-induced oxidative stress in liver mitochondria. Food and Chemical Toxicology 2010;48(7): 1973-9. http://www.ncbi.nlm.nih.gov/pubmed/20451574 (accessed 4 August 2014).

[115] Singh K, Malviya A, Bhori M, Marar T. An in vitro study of the ameliorative role of α-tocopherol on methotrexate-induced oxidative stress in rat heart mitochondria. Journal of Basic and Clinical Physiology and Pharmacology 2012;23(4): 163-8. http://www.ncbi.nlm.nih.gov/pubmed/23072846 (accessed 6 June 2014).

[116] Kolli V, Natarajan K, Isaac B, Selvakumar D, Abraham P. Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis. Human & Experimental Toxicology 2013. http://www.ncbi.nlm.nih.gov/pubmed/24347301 (accessed 13 August 2014).

[117] Sandborn WJ. State-of-the-art: Immunosuppression and biologic therapy. Digestive Diseases 2010;28(3): 536-42. http://www.ncbi.nlm.nih.gov/pubmed/20926883 (accessed 3 July 2014).

[118] King PD, Perry MC. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterology Clinics if North America 1995;24(4): 969-90. http://www.ncbi.nlm.nih.gov/pubmed/8749907 (accessed 18 August 2014).

[119] Tapner MJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. Journal of Hepatology 2004;40(3): 454-63. http://www.ncbi.nlm.nih.gov/pubmed/15123360 (accessed 7 August 2014).

[120] Stickel F, Kessebohm K, Weimann R, Seitz HK. Review of liver injury associated with dietary supplements. Liver International 2011;31(5):595-605. http://www.ncbi.nlm.nih.gov/pubmed/21457433 (accessed 12 July 2014).

[121] de-Medeiros BC, Strapasson E, Pasquini R, de-Medeiros CR. Effect of all-trans retinoic acid on newly diagnosed acute promyelocytic leukemia patients: results of a Brazilian center. Brazilian Journal of Medical and Biological Research 1998;31(12): 1537-43. http://www.ncbi.nlm.nih.gov/pubmed/9951549 (accessed 15 June 2014).

[122] Standeven AM, Beard RL, Johnson AT, Boehm MF, Escobar M, Heyman RA, Chandraratna RA. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic acid receptors. Fundamental and Applied Toxicology 1996;33(2): 264-71. http://www.ncbi.nlm.nih.gov/pubmed/8921345 (accessed 23 July 2014).

[123] Leo MA, Arai M, Sato M, Lieber CS. Hepatotoxicity of vitamin A and ethanol in the rat. Gastroenterology 1982;82(2): 194-205. http://www.ncbi.nlm.nih.gov/pubmed/6274729 (accessed 5 July 2014).

[124] de Oliveira MR, Oliveira MW, Lorenzi R, Fagundes da Rocha R, Fonseca Moreira JC. Short-term vitamin A supplementation at therapeutic doses induces a pro-oxidative state in the hepatic environment and facilitates calcium-ion-induced oxidative stress in rat liver mitochondria independently from permeability transition pore formation: detrimental effects of vitamin A supplementation on rat liver redox and bioenergetic states homeostasis. Cell Biology and Toxicology 2009;25(6): 545-60. http://www.ncbi.nlm.nih.gov/pubmed/19043787 (accessed 9 June 2014).

[125] Rigobello MP, Scutari G, Friso A, Barzon E, Artusi S, Bindoli A. Mitochondrial permeability transition and release of cytochrome c induced by retinoic acids. Biochemical Pharmacology 1999;58(4): 665-70. http://www.ncbi.nlm.nih.gov/pubmed/10413304 (accessed 19 July 2014).

[126] Notario B, Zamora M, Viñas O, Mampel T. All-trans-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Molecular Pharmacology 2003;63(1): 224-31. http://www.ncbi.nlm.nih.gov/pubmed/12488555 (accessed 5 July 2014).

[127] Ribeiro MP, Santos AE, Santos MS, Custódio JB. Effects of all-*trans*-retinoic acid on the permeability transition and bioenergetic functions of rat liver mitochondria in

combination with endoxifen. Life Sciences 2013;93(2-3): 96-107. http://www.ncbi.nlm.nih.gov/pubmed/23764110 (accessed 7 July 2014).

[128] Stillwell W, Nahmias S. Effect of retinol and retinoic acid on P/O ratios of coupled mitochondria. Biochemistry International 1983;6(3): 385-92. http://www.ncbi.nlm.nih.gov/pubmed/6679330 (accessed 7 June 2014).

[129] Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, Ardehali H. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. The Journal of Biological Chemistry 2009;284(4): 2080-7. http://www.ncbi.nlm.nih.gov/pubmed/19017630 (accessed 1 July 2014).

[130] Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370(9604): 2011-9. http://www.ncbi.nlm.nih.gov/pubmed/18083403 (accessed 19 June 2014).

[131] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine 2007;356(2): 125-34. http://www.ncbi.nlm.nih.gov/pubmed/17215530 (accessed 11 June 2014).

[132] Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicological Sciences 2008;106(1): 153-61. http://www.ncbi.nlm.nih.gov/pubmed/18664550 (accessed 14 July 2014).

[133] French KJ, Coatney RW, Renninger JP, Hu CX, Gales TL, Zhao S, Storck LM, Davis CB, McSurdy-Freed J, Chen E, Frazier KS. Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicologic Pathology 2010;38(5): 691-702. http://www.ncbi.nlm.nih.gov/pubmed/20616376 (accessed 6 July 2014).

[134] Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Experimental Neurology 2012;238(2): 225-34. http://www.ncbi.nlm.nih.gov/pubmed/11212281 (accessed 3 August 2014).

[135] Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, Taroni F, Lauria G. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Experimental Neurology 2008;214(2): 276-84. http://www.ncbi.nlm.nih.gov/pubmed/18809400 (accessed 31 July 2014).

[136] Waseem M, Parvez S. Mitochondrial dysfunction mediated cisplatin induced toxicity: modulatory role of curcumin. Food and Chemical Toxicology 2013;53: 334-42. http://www.ncbi.nlm.nih.gov/pubmed/23246825 (accessed 25 July 2014).

[137] Tatlidede E, Sehirli O, Velioğlu-Oğünc A, Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S, Sener G. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radical Research 2009;43(3):195-205. http://www.ncbi.nlm.nih.gov/pubmed/19169920 (accessed 21 June 2014).

[138] Bast A, Kaiserová H, den Hartog GJ, Haenen GR, van der Vijgh WJ. Protectors against doxorubicin-induced cardiotoxicity: flavonoids. Cell Biology and Toxicology 2007;23(1): 39-47. http://www.ncbi.nlm.nih.gov/pubmed/17063376 (accessed 4 June 2014).

[139] Zhang X, Peng X, Yu W, Hou S, Zhao Y, Zhang Z, Huang X, Wu K. Alpha-tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux. Cancer Letters 2011;307(2): 174-81. http://www.ncbi.nlm.nih.gov/pubmed/21536373 (accessed 6 June 2014).

[140] Liu QY, Tan BK. Dietary fish oil and vitamin E enhance doxorubicin effects in P388 tumor-bearing mice. Lipids 2002;37(6): 549-56. http://www.ncbi.nlm.nih.gov/pubmed/12120952 (accessed 31 July 2014).

[141] Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. Journal of the American College of Cardiology 2006;48(11): 2258-62. http://www.ncbi.nlm.nih.gov/pubmed/17161256 (accessed 12 June 2014).

[142] Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallace KB. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicology Applied Pharmacology 2004;200(2):159-68. http://www.ncbi.nlm.nih.gov/pubmed/15476868 (accessed 18 August 2014).

[143] Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F Zimeras S, Kyriakidis M, Ahimastos A. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. American Journal of Hematology 2010;85(11): 894-6. http://www.ncbi.nlm.nih.gov/pubmed/20872550 (accessed 7 August 2014).

[144] Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. Journal of Clinical Oncology 1997;15(4): 1333-40. http://www.ncbi.nlm.nih.gov/pubmed/9193324 (accessed 1 July 2014).

[145] Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA,

Gelber RD, Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England Journal of Medicine 2004;351(2): 145-53. http://www.ncbi.nlm.nih.gov/pubmed/15247354 (accessed 21 July 2014).

[146]   Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. Journal of Molecular and Cellular Cardiology 1994;26(9): 1179-85. http://www.ncbi.nlm.nih.gov/pubmed/7815460 (accessed 12 July 2014).

[147]   Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radical Biology & Medicine 2003;35(11): 1469-79. http://www.ncbi.nlm.nih.gov/pubmed/14642395 (accessed 9 August 2014).

[148]   Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111(13): 1601-10. http://www.ncbi.nlm.nih.gov/pubmed/15811867 (accessed 29 June 2014).

[149]   Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, White KL Jr, Gewirtz DA. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Research and Treatment 2010;124(2): 349-60. http://www.ncbi.nlm.nih.gov/pubmed/20155316 (accessed 6 July 2014).

[150]   Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, Dent P, Kukreja RC. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2010;107(42): 18202-7. http://www.ncbi.nlm.nih.gov/pubmed/20884855 (accessed 14 June 2014).

[151]   Silva FS, Ribeiro MP, Santos MS, Rocha-Pereira P, Santos-Silva A, Custódio JB. The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen. Journal of Bioenergetics and Biomembranes 2013;45(4): 383-96. http://www.ncbi.nlm.nih.gov/pubmed/23779226 (accessed 2 August 2014).

[152]   Silva FS, Ribeiro MP, Santos MS, Rocha-Pereira P, Santos-Silva A, Custódio JB. Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity. Toxicology 2013;306: 93-100. http://www.ncbi.nlm.nih.gov/pubmed/23384448 (accessed 15 July 2014).

[153]   Wetherall NT, Taylor CM. The effects of retinoid treatment and antiestrogens on the growth of T47D human breast cancer cells. European Journal of Cancer & Clinical Oncology 1986;22(1): 53-9. http://www.ncbi.nlm.nih.gov/pubmed/3007157 (accessed 1 August 2014).

[154]   Danforth DNJr. All trans-retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor beta to stimulate apoptosis in MCF-7 breast cancer

cells. The Journal of Endocrinology 2004; 183(2): 395-404. http://www.ncbi.nlm.nih.gov/pubmed/15531727 (accessed 21 June 2014).

[155] Wang Y, He QY, Chen H, Chiu JF. Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Experimental Cell Research 2007;313(2): 357-68. http://www.ncbi.nlm.nih.gov/pubmed/17098229 (accessed 21 July 2014).

[156] Koay DC, Zerillo C, Narayan M, Harris LN, DiGiovanna MP. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. Breast Cancer Research 2010;12(4): R62. http://www.ncbi.nlm.nih.gov/pubmed/20696059 (accessed 1 August 2014).

[157] Ribeiro MP, Silva FS, Paixão J, Santos AE, Custódio JB. The combination of the anti-estrogen endoxifen with all-*trans*-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells. European Journal of Pharmacology 2013;715(1-3): 354-62. http://www.ncbi.nlm.nih.gov/pubmed/23712006 (accessed 25 June 2014).

[158] Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nature Reviews Drug Discovery 2010;9(6): 447-64. http://www.ncbi.nlm.nih.gov/pubmed/20467424 (accessed 10 August 2014).

[159] Moreira PI, Custódio JB, Nunes E, Oliveira PJ, Moreno A, Seiça R, Oliveira CR, Santos MS. Mitochondria from distinct tissues are differently affected by 17β-estradiol and tamoxifen. The Journal of Steroid Biochemistry and Molecular Biology 2011;123(1-2): 8-16. http://www.ncbi.nlm.nih.gov/pubmed/20932907 (accessed 27 July 2014).